- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04489511
Study of STG-001 in Subjects With Stargardt Disease
April 24, 2021 updated by: Stargazer Pharmaceuticals, Inc.
A Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With Stargardt Disease (STGD1) Caused by Autosomal Recessive Mutation in ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene
This is an open-label, multicenter study in subjects with Stargardt disease, comparing 2 doses of STG-001 with regard to safety, pharmacokinetics and pharmacodynamics.
Study Overview
Detailed Description
This is an open-label, multicenter, active treatment study in approximately 12 subjects aged 18 to 55 years (inclusive) with STGD1, genotyped with a minimum of two ABCA4 gene mutations.
Treatment course of STG-001 at Dose 1 (Cohort 1) or Dose 2 (Cohort 2) testing doses will be administered once daily for 28 days.
Cohorts will run in parallel.
Subjects will receive their designated dose daily for 28 days and be monitored for safety measures during the dosing period and for an additional 28 days after dosing (through Day 56).
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85020
- Associated Retina Consultants
-
-
Florida
-
Gainesville, Florida, United States, 32607
- Vitreo Retinal Associates, P.A.
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Casey Eye Institute - OHSU
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Eye Center
-
-
Texas
-
Dallas, Texas, United States, 75231
- Retina Foundation of Southwest
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Understand the study procedures and agree to participate by providing written informed consent.
- STGD1 caused by autosomal recessive mutation in the ABCA4 gene (i.e. at least 2 mutations), confirmed genotypically by a fully accredited certified central genotyping laboratory.
- 18 to 55 years of age inclusive.
- Negative pregnancy testing for women of childbearing potential and highly effective double barrier contraception before, during, and for a period after study treatment as described in the clinical protocol.
- Primary study eye must have at least one well-demarcated area of significantly reduced autofluorescence as imaged by fundus autofluorescence (FAF)
In at least one eye and in the same eye:
- ETDRS BCVA of less than or equal to 0.4 logMAR (≤68 letters; 20/50 Snellen equivalent) and greater than or equal to 1.3 logMAR (≥19 letters; 20/400 Snellen equivalent); and
- Clinical evidence of a macular lesion phenotypically consistent with Stargardt Disease
- Naïve to investigational treatment for STGD1 with no history of gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips or intravitreal or sub-retinal injections. History of experimental oral therapy is allowed if it occurred greater than 3 months prior to Screening.
- Primary study eye must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging.
- In good general health, aside from STGD1, as judged by Investigator.
- Willing and able to comply with the protocol, including attending assessment visits.
Exclusion Criteria:
- The subject is an employee of the Sponsor or study site or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
- Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to Day 1 first dose. Herbal supplements and HRT must be discontinued 7 days prior to Day 1 first dose.
- Presence of any concurrent ocular disease that would affect study outcomes (e.g., severe cataracts; subjects can be enrolled 3 months after successful cataract surgery).
- Presence of any meaningful retinopathy/maculopathy/atrophy other than as a result of STGD1 in either eye as determined by the Investigator.
- Has taken non-approved items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) within 30 days of Screening.
- Use of medications that may interact with Vitamin A metabolism within 60 days of Screening.
- Participation in an oral interventional study of a vitamin A derivative up to 3 months prior to Screening.
- The subject had a history of vitamin A deficiency as defined based upon serum values less than 20 mcg/dl (0.7 μmol/L) or clinical signs during slit lamp examination (conjunctival or corneal xerosis; Bitot's spots; corneal ulcers or scarring not due to trauma or other secondary causes).
- Presence of significant cardiovascular or cerebrovascular disease, including stroke, within 12 months of entry.
- Has a clinically significant abnormal electrocardiogram (ECG), or has a corrected QT interval (QTc) that is 450 ms or greater.
- Resting heart rate outside specified limits (< 40/minute, > 100/min) upon repeated measurement.
- History of diabetes, hepatitis, pancreatitis, cirrhosis, liver failure, uncontrolled thyroid disease or hypervitaminosis A.
- Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region.
- Any major surgical procedure within one month of Screening or planned or anticipated surgery during the study period.
- Women who are pregnant, nursing, or planning to become pregnant during the study period.
- Uncontrolled blood pressure outside specified limits (90 mm Hg > Systolic > 140 mm Hg and/or 40 mm Hg > Diastolic > 90 mm Hg) upon repeated measurement.
- Clinically significant abnormal lab results at Screening, including liver function test (aspartate transaminase, alanine transaminase, bilirubin and alkaline phosphatase) greater than 1.5 x the upper limit of normal (ULN).
- Actively participating in an investigational therapy study or have received any investigational therapy within 60 days of Screening or 5 half-lives, whichever is longer.
- Known serious allergies to the fluorescein dye used to measure intraocular pressure, ocular dilating drops, topical ocular anesthetic, components of the STG-001 formulation or any history of anaphylaxis reaction.
- In the Investigator's assessment, any acute or chronic medical condition, psychiatric condition, physical examination finding or laboratory abnormality that might increase the risk associated with study participation or administration of study treatment or interfere with the interpretation of study results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose 1
STG-001 given orally at Dose 1 once a day for 28 days
|
Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
|
Experimental: Dose 2
STG-001 given orally at Dose 2 once a day for 28 days
|
Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety events and Tolerability of STG-001 from baseline to 28 days: adverse events
Time Frame: From baseline to 28 days
|
Safety and tolerability of 28 days of daily dosing of 2 doses of STG-001 assessed by Incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse events
|
From baseline to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) of STG-001 maximum plasma concentration (Cmax) at Day 28
Time Frame: From baseline to 28 days
|
Cmax of 2 doses of STG-001 after 28 days of daily dosing of STG-001 assessed by a validated STG-001 assay
|
From baseline to 28 days
|
Pharmacokinetics (PK) of STG-001 area under the curve (AUC) at Day 28
Time Frame: From baseline to 28 days
|
Exposure to STG-001 as assessed by calculated AUC of 2 doses of STG-001 after 28 days of daily dosing of STG-001
|
From baseline to 28 days
|
Pharmacodynamics (PD) of STG-001 change in plasma Retinol-Binding Protein 4 (RBP4) at Day 28
Time Frame: From baseline to 28 days
|
Change in Plasma RBP4 levels from baseline to Day 28 with 2 doses of STG-001 after 28 days of daily dosing of STG-001
|
From baseline to 28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Prinicpal Investigator, MD, Study Site Director
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Actual)
April 24, 2021
Study Completion (Actual)
April 24, 2021
Study Registration Dates
First Submitted
July 21, 2020
First Submitted That Met QC Criteria
July 27, 2020
First Posted (Actual)
July 28, 2020
Study Record Updates
Last Update Posted (Actual)
April 27, 2021
Last Update Submitted That Met QC Criteria
April 24, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STG-001-2a
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stargardt Disease-1
-
Institute of Molecular and Clinical Ophthalmology...RecruitingStargardt Disease | Stargardt Disease 1 | Fundus Flavimaculatus | Macular Degeneration, Stargardt | Macular Dystrophy With Flecks, Type 1Switzerland
-
Alkeus Pharmaceuticals, Inc.RecruitingStargardt Disease | Stargardt Macular Degeneration | Stargardt Macular Dystrophy | Autosomal Recessive Stargardt Disease 1 (ABCA4-related)United States
-
Alkeus Pharmaceuticals, Inc.Enrolling by invitationStargardt Disease | Stargardt Macular Degeneration | Stargardt Macular Dystrophy | Autosomal Recessive Stargardt Disease 1 (ABCA4-related)United States
-
West China HospitalActive, not recruiting
-
Belite Bio, IncActive, not recruitingStargardt Disease 1United States, Australia, Belgium, China, France, Germany, Hong Kong, Netherlands, Switzerland, Taiwan, United Kingdom
-
IVERIC bio, Inc.Active, not recruitingStargardt Disease 1Italy, United States, Israel, United Kingdom, Germany, Spain, Hungary, France
-
Ophthalmos Research and Education InstituteCompletedStargardt Disease 1 | Dry AMDFrance, Germany, Italy
-
Pomeranian Medical University SzczecinUnknownRetinal Degeneration | Retinitis Pigmentosa | Age Related Macular Degeneration | Stargardt Disease 1Poland
-
Queen's University, BelfastUniversity of SussexUnknownRetinitis Pigmentosa | Low Vision | Albinism | Stargardt Disease 1 | Stargardt Disease 3 | Stargardt Disease 4United Kingdom
-
Barcelona Macula FoundationRecruitingRetinitis Pigmentosa | Choroideremia | Stargardt Disease 1 | Best Disease | Pattern Dystrophy of MaculaSpain
Clinical Trials on STG-001
-
Boston VA Research Institute, Inc.Mclean Hospital; Cambridge Health Alliance; Northeastern UniversityRecruitingSchizophrenia | Treatment-resistant Schizophrenia | Auditory HallucinationUnited States
-
Universidade Federal de Sao CarlosUnknownPatellofemoral Pain SyndromeBrazil
-
Panam ClinicCompletedIsolated Anterior Cruciate Ligament RuptureCanada
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China